TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, raised $50 million by offering 7.2 million shares at $7. TetraLogic Pharmaceuticals plans to list on the NASDAQ under the symbol TLOG. TetraLogic Pharmaceuticals initially filed confidentially on 9/16/2013. Oppenheimer & Co., Guggenheim Securities and Needham & Co. acted as lead managers on the deal.
